Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 4/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26967397 | 0.85 | — | — | |
| SCHEMBL28501434 | 0.83 | NQO2 (0.36) | NQO2NSD2CASP6ERN1ALOX5 | |
| SCHEMBL24616483 | 0.82 | — | — | |
| SCHEMBL24616382 | 0.80 | — | — | |
| SCHEMBL22029150 | 0.79 | — | — | |
| SCHEMBL29937105 | 0.79 | — | — | |
| SCHEMBL24616380 | 0.76 | — | — | |
| SCHEMBL22029169 | 0.76 | — | — | |
| SCHEMBL22715357 | 0.76 | NQO2 (0.44) | NQO2ERN1ALOX5PTGS2 | |
| SCHEMBL30615098 | 0.76 | ADORA2A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246954-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | THERAS, INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4294799-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-117157290-A | Compositions and methods for inhibiting KRAS | 瑟拉斯有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023104018-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUND AS KRAS G12D INHIBITOR | 苏州浦合医药科技有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2022177917-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246954-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | KRAS, NRAS, HRAS | NQO2 1049/4885ESR1 1121/4885ESR2 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.